Source: Tufts Clinical and Translational Science Institute

Type: Online Course

Level: Intermediate

Description: “After completing this lecture, you will be able to:
Identify the need for comparative effectiveness trials, even for drug therapies where “”proof of efficacy”" is already required prior to approval
Explain the differences between pragmatic/effectiveness trials and explanatory/efficacy trials
List the strengths and limitations of pragmatic versus explanatory designs
State the strengths and limitations of various types of outcome measures, including surrogate versus clinical outcomes
Explain the difference between prognostic and predictive genetic markers
Identify the pros and cons of alternative research designs for assessing pharmacogenetic (predictive) effects
Discuss “repurposed” randomized trials for assessing pharmacogenetic effects
Define empirical data”

Source: Tufts Clinical and Translational Science Institute

Type: Online Course

Level: Intermediate

Description: “After completing this lecture, you will be able to: List the principles of Evidence-Based Medicine (EBM), state how CER extends the principles of EBM, describe a framework for understanding the CER agenda, and identify the stakeholders of CER”.

Source: Tufts Clinical and Translational Science Institute

Type: Online Course

Level: Intermediate

Description: “After completing this lecture, you will be able to:
Define CER based on standard definitions and the typical activities that it encompasses
Review the motivations, accomplishments, and impediments for CER
Describe how CER is supported in the United States now and how the new Patient-Centered Outcomes Research Institute will support CER
Identify the roles for CTSAs in facilitating and implementing CER
Discuss specific needs, next steps, and the future of CER
Identify the forces shaping national priorities for CER in the United States
Explain the current CER landscape in the United States
Compare and contrast comparative effectiveness and cost-effectiveness research”